托法替布治疗难治性成人斯蒂尔病：来自中国单中心的14例病例 - Suppr

Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.

作者信息

Hu Qiongyi, Wang Mengyan, Jia Jinchao, Teng Jialin, Chi Huihui, Liu Tingting, Liu Hong-Lei, Cheng Xiaobing, Ye Junna, Su Yutong, Sun Yue, Zhou Zhuochao, Wan Liyan, Wang Zhihong, Wang Fan, Shi Hui, Yang Chengde

机构信息

Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

出版信息

Ann Rheum Dis. 2020 Jun;79(6):842-844. doi: 10.1136/annrheumdis-2019-216699. Epub 2020 Feb 20.

DOI:10.1136/annrheumdis-2019-216699

PMID:32079571

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7286046/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1241/7286046/30cb4c723999/annrheumdis-2019-216699f01.jpg

相似文献

Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.托法替布治疗难治性成人斯蒂尔病：来自中国单中心的14例病例

Ann Rheum Dis. 2020 Jun;79(6):842-844. doi: 10.1136/annrheumdis-2019-216699. Epub 2020 Feb 20.

Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome.托法替布诱导难治性成人斯蒂尔病合并巨噬细胞活化综合征缓解。

Scand J Rheumatol. 2020 Jul;49(4):336-338. doi: 10.1080/03009742.2020.1729405. Epub 2020 Apr 24.

[Successful treatment of adult Still's disease with tofacitinib in a HIV-2 positive female patient].[托法替布成功治疗一名HIV-2阳性成年女性患者的成人斯蒂尔病]

Z Rheumatol. 2020 Dec;79(10):1046-1049. doi: 10.1007/s00393-020-00853-9.

JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.JAK抑制剂在难治性成人斯蒂尔病和全身型幼年特发性关节炎中的应用

Rheumatology (Oxford). 2023 Apr 3;62(4):1594-1604. doi: 10.1093/rheumatology/keac440.

Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.难治性皮肤性皮肌炎的治疗：托法替尼的 Janus 激酶抑制作用的潜在作用。

Rheumatology (Oxford). 2019 Jun 1;58(6):1011-1015. doi: 10.1093/rheumatology/key366.

Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis.Janus激酶抑制剂托法替布是难治性嗜酸性筋膜炎的一种潜在治疗选择。

Clin Exp Rheumatol. 2020 May-Jun;38(3):567-568. Epub 2019 Nov 18.

Reversal of Alopecia Universalis by Tofacitinib: A Case Report.托法替布治疗全秃症逆转：一例报告

Ann Intern Med. 2016 Nov 15;165(10):750-751. doi: 10.7326/L16-0125.

Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia.伊马替尼治疗慢性粒细胞白血病患者时成人斯蒂尔病获得长期缓解

J Rheumatol. 2009 Jun;36(6):1349-51. doi: 10.3899/jrheum.081159.

Cyclosporin A in the treatment of adult Still's disease.环孢素A治疗成人斯蒂尔病。

J Rheumatol. 1995 Jul;22(7):1391-2.

Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.使用JAK抑制剂托法替布和芦可替尼治疗伴有皮肤受累的高嗜酸性粒细胞综合征。

J Invest Dermatol. 2017 Apr;137(4):951-954. doi: 10.1016/j.jid.2016.10.044. Epub 2016 Nov 22.

引用本文的文献

Tofacitinib in the Treatment of Refractory Adult-Onset Still's Disease Co-diagnosed With Celiac Disease: A Case Report.托法替布治疗合并乳糜泻的难治性成人斯蒂尔病：一例报告

Cureus. 2025 May 25;17(5):e84770. doi: 10.7759/cureus.84770. eCollection 2025 May.

Tofacitinib as a possible treatment in macrophage activation syndrome: a pilot single-center study in China.托法替布作为巨噬细胞活化综合征的一种可能治疗方法：中国一项单中心试点研究

Clin Rheumatol. 2025 May 8. doi: 10.1007/s10067-025-07465-1.

Characterization of Genetic Landscape and Novel Inflammatory Biomarkers in Patients With Adult-Onset Still's Disease.成人斯蒂尔病患者的遗传图谱及新型炎症生物标志物特征分析

Arthritis Rheumatol. 2025 May;77(5):582-595. doi: 10.1002/art.43054. Epub 2024 Dec 16.

A Case Report of JAK Inhibitors Therapy for Adult-Onset Still's Disease with Persistent Pruritic Lesions.成人Still 病伴持续瘙痒皮损采用 JAK 抑制剂治疗 1 例报告

Drugs R D. 2024 Sep;24(3):391-394. doi: 10.1007/s40268-024-00487-1. Epub 2024 Sep 18.

Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease Continuum.将系统性幼年特发性关节炎和成人斯蒂尔病作为斯蒂尔病连续谱的一部分进行诊断和治疗。

Mediterr J Rheumatol. 2024 Mar 30;35(Suppl 1):45-57. doi: 10.31138/mjr.290323.dat. eCollection 2024 Mar.

Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options.成人Still 病（AOSD）：对发病机制、遗传学和新兴治疗选择的理解的进展。

Drugs. 2024 Mar;84(3):257-274. doi: 10.1007/s40265-024-01993-x. Epub 2024 Mar 5.

Interrupting an IFN-γ-dependent feedback loop in the syndrome of pyogenic arthritis with pyoderma gangrenosum and acne.中断化脓性关节炎、坏疽性脓皮病和痤疮综合征中 IFN-γ 依赖性反馈环。

Ann Rheum Dis. 2024 May 15;83(6):787-798. doi: 10.1136/ard-2023-225085.

Case Report: Refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia.病例报告：难治性巨噬细胞活化综合征，在与腺病毒血症相关的早发性全身型幼年特发性关节炎中需要大剂量阿那白滞素、依帕珠单抗和依托泊苷治疗。

Front Pediatr. 2024 Jan 22;11:1336554. doi: 10.3389/fped.2023.1336554. eCollection 2023.

Tofacitinib for the treatment of severe rare skin diseases: a narrative review.托法替尼治疗严重罕见皮肤病：叙述性综述。

Eur J Clin Pharmacol. 2024 Apr;80(4):481-492. doi: 10.1007/s00228-024-03621-9. Epub 2024 Jan 17.

Recent advances and evolving concepts in Still's disease.斯蒂尔病的最新进展和不断发展的概念。

Nat Rev Rheumatol. 2024 Feb;20(2):116-132. doi: 10.1038/s41584-023-01065-6. Epub 2024 Jan 11.

本文引用的文献

Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease.MS评分在成人斯蒂尔病相关巨噬细胞活化综合征患者中的应用。

Ann Rheum Dis. 2021 Sep;80(9):e145. doi: 10.1136/annrheumdis-2019-216286. Epub 2019 Oct 14.

JAK inhibitors for the treatment of autoimmune and inflammatory diseases.JAK 抑制剂治疗自身免疫性和炎症性疾病。

Autoimmun Rev. 2019 Nov;18(11):102390. doi: 10.1016/j.autrev.2019.102390. Epub 2019 Sep 11.

Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis.托法替尼治疗难治性全身型幼年特发性关节炎。

Pediatrics. 2019 May;143(5). doi: 10.1542/peds.2018-2845. Epub 2019 Apr 4.

Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy.成人斯蒂尔病的生物治疗策略可能取决于表型二分法。

Arthritis Res Ther. 2019 Feb 12;21(1):53. doi: 10.1186/s13075-019-1838-6.

A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function.JAK1 选择性激酶抑制剂和托法替尼对巨噬细胞激活和功能的影响。

Inflamm Bowel Dis. 2019 Mar 14;25(4):647-660. doi: 10.1093/ibd/izy364.

Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still's disease.中性粒细胞胞外诱捕网增加激活成年Still 病中的 NLRP3 和炎性巨噬细胞。

Arthritis Res Ther. 2019 Jan 7;21(1):9. doi: 10.1186/s13075-018-1800-z.

Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy.联合使用阿那白滞素和巴瑞替尼治疗难治性成人斯蒂尔病。

Rheumatology (Oxford). 2019 Apr 1;58(4):736-737. doi: 10.1093/rheumatology/key414.

Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils.托法替布抑制粒细胞-巨噬细胞集落刺激因子诱导的人中性粒细胞中 NLRP3 炎性体的激活。

Arthritis Res Ther. 2018 Aug 29;20(1):196. doi: 10.1186/s13075-018-1685-x.

A Pilot Study on Tocilizumab for Treating Refractory Adult-Onset Still's Disease.托珠单抗治疗难治性成人斯蒂尔病的一项初步研究。

Sci Rep. 2017 Oct 18;7(1):13477. doi: 10.1038/s41598-017-13639-y.

Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis.临床表现而非细胞因子谱可区分成人斯蒂尔病和脓毒症。

J Rheumatol. 2010 Nov;37(11):2369-76. doi: 10.3899/jrheum.100247. Epub 2010 Sep 1.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献